Pomerantz Law Firm Investigates Johnson & Johnson Following Q3 2026 Financial Results
Pomerantz LLP has launched an investigation into Johnson & Johnson (JNJ) regarding potential securities fraud or unlawful business practices. The probe follows the company's third-quarter 2026 financial report, which revealed a significant drop in GAAP net earnings to $210 million ($0.09 per share). This decline was primarily driven by multi-billion dollar special charges related to ongoing talc litigation settlements. Additionally, J&J reported underperformance in its MedTech segment, which saw revenue growth of only 2.5% due to pricing constraints in China and geopolitical instability in the Middle East. Following these disclosures on October 13, 2026, JNJ shares fell by 5.73%, closing at $248.61 per share.
Tickers: $JNJ
Topics: class action lawsuit earnings miss MedTech revenue decline securities fraud investigation talc litigation